AARD

Aardvark Therapeutics, Inc.
CAPPED RATING

Aardvark Therapeutics, Inc. (AARD) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D). The rating has held at C for 11 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B+
Factor Score 3.7 / 5.0
Growth
C
Factor Score 2.4 / 5.0
Profitability
C-
Factor Score 1.9 / 5.0
Momentum
D
Factor Score 1.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.5
EV / EBITDA 0.6
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -79.5%
Price Return 12M -88.4%
Catalyst Signal 0.00
Market Cap $27.6M
TTM Revenue N/A
Price / Sales N/A
ROE -66.0%

Historical Factor Score Progression

Held C for 11 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B+ (3.7) C (2.4) C- (1.9) D (1.2) C+ (2.6) C (2.3)
2026-11-10 B+ (3.8) C (2.3) C- (1.9) D (1.2) C+ (2.6) C (2.4)
2026-11-03 B+ (3.7) C (2.3) C- (1.9) D (1.3) C+ (2.7) C (2.4)
2026-10-27 B+ (3.7) C (2.2) C- (1.9) D (1.2) C+ (2.6) C (2.3)
2026-10-20 C+ (2.5) C (2.2) C- (1.9) D+ (1.7) C+ (2.6) C (2.2)
Page 1 of 4